Financial Performance - Q2 2025 - Total revenue for Q2 2025 increased by 7% year-over-year, reaching $103 million[20] - Clinical Solutions revenue increased significantly by 32% compared to Q2 2024[21] - Gross margin improved from 292% in Q2 2024 to 387% in Q2 2025[23] - Adjusted EBITDA improved from a loss of $26 million in Q2 2024 to a loss of $08 million in Q2 2025[26] - Free cash flow improved from a negative $30 million in Q2 2024 to a negative $23 million in Q2 2025[28] Revenue Breakdown - 2024 - Catalog products accounted for approximately 60% of total revenue in 2024[14, 15] - Custom products represented about 35% of total revenue in 2024, with biopharma contributing 70% of custom revenue and 25% of total revenue[14, 15] - Other revenue, including services and shipping, made up roughly 5% of total revenue in 2024[14, 15] Customer Migration and Spending - Customers purchasing GMP reagents spent 44 times more annually compared to catalog-only customers in 2024[17] - 58% of 2024 revenue came from custom and/or clinical accounts[17] - 27% of 2024 revenue was generated from Cell and Gene Therapy (CGT) customers[17] 2025 Outlook - The company estimates total revenue between $39 million and $42 million, representing a 7% year-over-year increase at the midpoint[41] - The company is targeting a free cash outflow of less than $12 million for 2025[41] - The company estimates an annualized revenue range of $50 million to $55 million to achieve Adjusted EBITDA break-even[41]

Q2 2025 FINANCIAL RESULTS Safe Harbor/Disclosure Statement These materials contain forward-looking statements relating to, among other things, the future performance of The RealReal that are based on the company's current expectations, forecasts and assumptions and involve risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expect," "plan," "anticipate," "target," "contemplate," "project," "believe," "estimate," "predi ...

Investor Presentation Q2 2025 As of August 7, 2025 home, family, planet, healthier. Your Grove's transformation fuels momentum for future growth Safe Harbor Statement/Non-GAAP Measures All information in this presentation is as of August 7, 2025. Forward-Looking Statements Certain statements included in this presentation are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements ...

What we do We provide a platform for ad buyers. Most buyers are ad agencies, brands, or other technology companies. INVESTOR RELATIONS PRESENTATION Second Quarter 2025 Statement of caution under the Private Securities Litigation Reform Act of 1995 This document contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to expectations concerning matters that (a) are not historical facts, (b) predict or forecast future events or r ...

Financial Performance - Consolidated revenue increased by 0.3%, reaching $87.721 million in Q2'25[33, 42] - Adjusted EBITDA decreased by 2.1% year-over-year, totaling $48.065 million, with an adjusted EBITDA margin of 54.8%[33, 50] - Adjusted EPS increased by 2.0% year-over-year[33] - Free cash flow for Q2'25 was $20.3 million, compared to $15.8 million in Q2'24[36] Corporate Business - Corporate revenue increased by 6.9% to $55.3 million in Q2'25, compared to $51.7 million in Q2'24[13] - Corporate revenue retention rate improved to 102% in Q2'25, up from 99% in Q2'24[13] - Total corporate customer count increased to 63,000 in Q2'25, compared to 56,000 in Q2'24, an 11.3% increase[13, 20] SoHo Business - SoHo revenue decreased to $32.4 million in Q2'25, compared to $35.8 million in the previous year, a 9.4% decline[16] - SoHo account base was 682,000 in Q2'25, compared to 702,000 in Q1'25[16] - SoHo churn rate increased to 3.84% in Q2'25, compared to 3.52% in Q1'25[16] Capital Allocation - The company repurchased 546,000 shares for approximately $12 million in Q2'25[36] - Bond repurchases in Q2'25 amounted to approximately $6 million face value[36] - A $225 million credit facility was executed, including a $150 million delayed draw term loan and a $75 million revolving credit facility[36]

Strategic Divestments - StoneCo divested Linx and related assets to TOTVS for an enterprise value of R$305 billion and a total value of R$341 billion[12] - SimplesVet was divested to PetLove for an enterprise value of R$140 million and a total value of R$155 million[12] - The value captured from divestments represents approximately 25% of StoneCo's market capitalization, while the divested assets accounted for less than 5% of the company's adjusted net income[11, 14] Financial Performance (2Q25) - StoneCo's adjusted basic EPS for continuing operations increased by 409% year-over-year[20, 45] - Adjusted net income from continuing operations increased by 237% year-over-year to R$5981 million[20, 39] - Total revenue and income from continuing operations grew by 202% year-over-year to R$35009 million[34, 39] - Adjusted gross profit from continuing operations increased by 139% year-over-year to R$15615 million[39] Business Segments - MSMB (Micro, Small, and Medium Businesses) payments client base increased by 64% year-over-year[26] - MSMB TPV (Total Payment Volume) increased by 12% year-over-year[26] - Retail deposits increased by 36% year-over-year[28] - Credit portfolio increased by 25% quarter-over-quarter[30] Guidance Update - StoneCo updated its 2025 adjusted gross profit guidance to > R$6375 billion, reflecting a 145% year-over-year increase[17] - The company updated its 2025 adjusted basic EPS guidance to > R$96 per share, representing a 32% year-over-year increase[17] Future Outlook (2027 Guidance) - StoneCo projects MSMB TPV to exceed R$670 billion by 2027, with a CAGR of +14%[46] - The company anticipates retail deposits to surpass R$140 billion by 2027, with a CAGR of +17%[46] - StoneCo expects its credit portfolio to exceed R$55 billion by 2027, with a CAGR of +66%[46] - The company forecasts adjusted gross profit to exceed R$102 billion by 2027, with a CAGR of +18%[46] - StoneCo projects adjusted basic EPS to exceed R$150 per share by 2027, with a CAGR of +27%[46]

Q2 2025 Financial Performance - Total revenue reached $61.7 million, a 22% increase year-over-year and a 19% increase quarter-over-quarter[10] - Aerospace & Defense (A&D) revenue hit a record $40.7 million, up 49% year-over-year and 24% quarter-over-quarter[10] - Product revenue in A&D reached a record $19.8 million, a 75% increase year-over-year and 18% quarter-over-quarter[10] - Development revenue reached a record $20.9 million, a 30% increase year-over-year and 31% quarter-over-quarter[10] - Total gross margin was 29.9%, with product gross margin at 38.5%[10] - Adjusted EBITDA was $5.6 million[10] - The company holds a strong balance sheet with $113.7 million in cash and marketable securities[10] Revenue Breakdown by Market - A&D accounted for 66% of total revenue in Q2 2025[12] - Industrial revenue was $9.7 million, a 25% decrease year-over-year but a 10% increase quarter-over-quarter, representing 16% of total revenue[12] - Microfabrication revenue was $11.3 million, an 11% increase year-over-year and a 12% increase quarter-over-quarter, representing 18% of total revenue[12] Q3 2025 Outlook - The company projects Q3 2025 revenues between $62 million and $67 million, with a midpoint of $64.5 million[24] - Q3 2025 gross margin is expected to be between 24% and 30%[24] - Adjusted EBITDA for Q3 2025 is projected to be between $2.0 million and $6.0 million[24]

Q3 FY25 Financial Performance - Revenue reached $203 million, a decrease of 3% year-over-year[7, 9] - Non-GAAP gross margin improved to 34%, a 100 bps increase year-over-year[7, 9] - Non-GAAP EPS increased to $0.18, a 29% increase year-over-year[7, 10] - Adjusted EBITDA increased to $29 million, a 27% increase year-over-year[13] - The company paid off $200 million in convertible notes on June 2[7] Balance Sheet and Cash Flow - Cash, cash equivalents, and marketable securities totaled $153 million[7, 8] - Adjusted EBITDA for the trailing twelve months (TTM) was $110 million[31] - Net debt leverage (TTM) was 20x[31] Segment and Geographic Revenue Mix - Medical segment revenue was $142 million[19, 21] - Industrial segment revenue was $61 million[19, 21] - Revenue from the Americas was $71 million[20, 22] Q4 FY25 Guidance - Revenue is projected to be between $210 million and $230 million[34] - Non-GAAP EPS is expected to be between $010 and $030[34]

Q2 2025 Financial Results - Paid tickets were 197 million, a decrease of 7% year-over-year[12, 18, 19] - Gross ticket sales reached $755 million[12] - Net revenue totaled $728 million, down 14% year-over-year[14, 29, 31] - The net loss was $21 million, compared to a net income of $11 million in the prior year, but improved year-over-year excluding a one-time litigation settlement gain in Q2 2024[13, 33, 34] - Adjusted EBITDA was $64 million, with an Adjusted EBITDA margin of 88%[13, 36, 38] - Operating expenses decreased by 16% year-over-year to $554 million[40, 41] Operational Metrics - Paid creators numbered 1683K, a decrease of 5% year-over-year[15, 21, 22] - Average Monthly Active Users (MAUs) were 912 million, a decrease of 2% year-over-year[23, 25] Debt and Liquidity - Debt outstanding was $241 million, a 33% decrease year-over-year[46, 47, 114] - Available liquidity was $248 million, a $7 million increase from Q1 2025[49, 50, 114] 2025 Business Outlook - The company anticipates net revenue for Q3 2025 to be in the range of $70 million to $73 million with an Adjusted EBITDA margin of approximately 7%[52] - For fiscal year 2025, the company expects to achieve monthly year-over-year growth in paid ticket volume by the end of the year and updated the net revenue outlook range to $290 million to $296 million with an Adjusted EBITDA margin outlook of approximately 7%[53]

WM Technology, Inc. Q2 2025 Results August 7, 2025 Disclaimer This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to WM Technology, Inc. ("WM", the "Company", "we", "us", "our") and for no other purpose. References in this presentation to the "10- Q" refer to the Quarterly Report on Form 10-Q for the period ended June 30, 2025 to be filed with the Securities and Exchange Commission (the "SEC"). No repres ...